Evotec's Restructuring Gamble: 800 Job Cuts and a Race Against the Clock
Published on 07/30/2026 at 17:43 | Redaktion boerse-global.de
The numbers tell a grim story, but the narrative is far from settled. Evotec's stock is trading at €3.49, down nearly 36% since January and a staggering 55% below its 52-week high of €7.75. Yet beneath the surface of this battered share price lies a company attempting one of the most radical transformations in its history — a pivot that will determine whether it emerges leaner and stronger or continues to bleed value.
The trigger for the current crisis came on July 13, when management slashed its 2026 revenue forecast from a range of €700-780 million down to €570-610 million. The adjusted EBITDA projection took an even more brutal hit, collapsing from a forecast of breakeven to a positive €40 million into a loss of €70-105 million. Preliminary half-year results confirmed the damage: revenue of €300.1 million against an adjusted EBITDA loss of roughly €42.7 million.
A Split in the Investor Ranks
The market's reaction has been anything but uniform. One camp sees the guidance cut as a temporary timing issue — roughly 40% of the shortfall stems from delayed milestone payments, while another 45% comes from postponed strategic partnerships that, crucially, have not been cancelled. If these deals close in the second half, the current forecasts could prove conservative, creating significant upside for a stock already showing technical signs of being oversold.
The other camp sees something more sinister: structural weakness. If partners are hesitating because they doubt Evotec's business model or financial stability, the delays could be permanent rather than temporary. Deutsche Bank Research added to the bearish case on July 16, slashing its price target from €4.50 to €3.50 while maintaining a "Hold" rating — hardly a vote of confidence in a rapid recovery.
Should investors sell immediately? Or is it worth buying Evotec?
The "Horizon" Strategy Takes Shape
Against this turbulent backdrop, CEO Mario Polywka is pushing ahead with "Horizon," a radical restructuring plan that aims to transform Evotec into an asset-light drug discovery powerhouse. The strategy involves shedding expensive manufacturing sites while doubling down on high-margin research activities.
The human cost is substantial: approximately 800 jobs will be eliminated globally as the company shrinks its network of facilities to just ten centers. Management expects these cuts to generate annual savings of roughly €75 million by the end of 2027. First steps have already been taken — the sale of the Toulouse site and the divestment of the Tubulis stake have brought in fresh capital, with liquidity expected to reach an estimated €465.6 million by June 30, 2026.
A Bright Spot in the Core Business
Not everything is going wrong. The "Discovery & Preclinical Development" segment posted net sales growth of over 20% in the first half, according to analyst reports. This suggests that Evotec's fundamental research capabilities remain in demand, even as the broader restructuring creates uncertainty.
There are also signs of operational continuity. Just – Evotec Biologics launched "J.TRAIN" at the end of June, an offering that allows partners to use the company's proprietary continuous manufacturing technology in their own facilities. On the leadership front, Claire Hinshelwood stepped in as CFO in May following Paul Hitchin's departure in April, while the June annual general meeting confirmed a broadened supervisory board.
The Technical Picture: Oversold but Not Out
The stock's relative strength index (RSI) stands at 28.4, firmly in oversold territory. But technical indicators alone rarely signal a sustainable bottom, and the chart tells a sobering story: the share price is trading 24.29% below its 50-day moving average and 33.96% below the 200-day average — levels that typically reflect deep-seated investor skepticism rather than a pending reversal.
Evotec at a turning point? This analysis reveals what investors need to know now.
The €3 mark has emerged as a critical support level, with the stock currently trading just 8.52% above its 52-week low of €3.19 hit on July 14. A break below that floor could trigger another wave of selling.
What Comes Next
The full half-year report, due in August, will be the next major catalyst. Investors will be looking for confirmation of the preliminary numbers and, more importantly, concrete updates on the delayed partnerships. If management can demonstrate that the deals are progressing, the current share price could look like a buying opportunity. If not, the bearish case will gain further traction.
For now, Evotec remains a high-stakes bet on a turnaround that has yet to prove itself. The restructuring plan is ambitious, the core business is growing, and the balance sheet has been bolstered by asset sales. But with 800 jobs on the line, a management team that has lost credibility on forecasting, and a stock that has shed more than half its value in a year, the margin for error is razor-thin.
Ad
Evotec Stock: New Analysis - 30 July
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
